Publications by authors named "Bachelez H"
Introduction: Risankizumab has demonstrated a favourable safety profile in patients with psoriatic disease (moderate-to-severe psoriasis [PsO] and psoriatic arthritis [PsA]). We evaluated the long-term safety of risankizumab in psoriatic disease.
Methods: Long-term safety was evaluated by analysing data from 20 (phase 1-4) clinical trials for plaque PsO and four (phase 2-3) trials for PsA.
Article Synopsis
- * Researchers discovered that the hormone hepcidin is highly expressed in the skin of psoriasis patients, particularly those with treatment-resistant pustular forms.
- * In experiments with mice, high levels of hepcidin in skin cells caused excessive skin growth and immune cell attraction, suggesting hepcidin plays a key role in psoriasis and could be a target for new treatments.
EFFISAYIL 1 was a randomized, placebo-controlled study of spesolimab, an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare. Treatment with spesolimab led to more rapid pustular and skin clearance versus treatment with placebo in approximately half of the patients. In this study, we present histologic, transcriptomic, and proteomic analyses of lesional and nonlesional skin and whole-blood samples collected from EFFISAYIL 1.
View Article and Find Full Text PDFImportance: Generalized pustular psoriasis (GPP) lacks internationally accepted definitions and diagnostic criteria, impeding timely diagnosis and treatment and hindering cross-regional clinical and epidemiological study comparisons.
Objective: To develop an international consensus definition and diagnostic criteria for GPP using the modified Delphi method.
Evidence Review: The rarity of GPP presents a challenge in acquiring comprehensive published clinical data necessary for developing standardized definition and criteria.
Background: GPP is a rare, chronic, neutrophilic skin disease, with limited real-world data characterizing patients with flares and the impact of flares on disease progression and morbidity.
Objective: Describe the clinical characteristics of patients with GPP, comorbidities, disease epidemiology and frequency and severity of flares, and compare patients with GPP with a matched severe psoriasis population.
Methods: In this population-based real-world cohort study an algorithm was developed to identify patients with GPP flares.
Background: Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis.
Objectives: To evaluate the long-term efficacy of risankizumab according to baseline patient characteristics, and for the treatment of high-impact disease manifestations (nail, scalp and palmoplantar psoriasis), through 256 weeks of continuous treatment in the phase 3 LIMMitless study.
Tissue transcriptomics is used to uncover molecular dysregulations underlying diseases. However, the majority of transcriptomics studies focus on single diseases with limited relevance for understanding the molecular relationship between diseases or for identifying disease-specific markers. In this study, we used a normalization approach to compare gene expression across nine inflammatory skin diseases.
View Article and Find Full Text PDFBackground: Little is known about phototype and the response to systemic treatment in psoriasis.
Objectives: To assess the characteristics of psoriasis, the therapeutic choice and its efficacy according to phototype.
Methods: We included patients from the PsoBioTeq cohort initiating a first biologic.
Article Synopsis
- Lichen planus (LP) is a chronic inflammatory skin and mucosal disease linked to specific T-lymphocyte activity, particularly involving CD8 cytotoxic T-lymphocytes (CTL), and may have an association with HPV16.
- In patients with LP, researchers found activated CTL specific to HPV16 in lesions, indicating a potential role of this virus across various forms of LP, not just in erosive oral LP.
- Contrarily, lichen sclerosus et atrophicus (LSA) patients show a different immune response, with distinct CTL populations and antibody profiles, suggesting a different pathogenic mechanism compared to LP.
Background: The nature of the COVID-19 pandemic led to concerns among patients and physicians about the potential impact of immunosuppressive treatments for chronic diseases such as psoriasis on the risk of severe COVID-19.
Objectives: To describe treatment modifications and determine the incidence of COVID-19 infection among psoriasis patients during the first wave of the pandemic, and identify the factors associated with these events.
Methods: Data from PSOBIOTEQ cohort relating to the first COVID-19 wave in France (March to June, 2020), as well as a patient-centred COVID-19 questionnaire, were used to evaluate the impact of lockdown on changes (discontinuations, delays or reductions) in systemic therapies, and to determine the incidence of COVID-19 cases among these patients.
Background: Effisayil 1 was a randomized, placebo-controlled study of spesolimab, which is an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare.
Objective: To assess the effects of spesolimab over the 12-week study.
Methods: The primary endpoint of the study was Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 at week 1.
Background: Generalized pustular psoriasis (GPP) is a rare and life-threatening skin disease often accompanied by systemic inflammation. There are currently no standardized or validated GPP-specific measures for assessing severity.
Objective: To evaluate the reliability, validity and responder definitions of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) and Generalized Pustular Psoriasis Area and Severity Index (GPPASI).
Background: Generalized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares with current treatment options.
Objective: The aim of the study was to describe the characteristics and outcomes of GPP flares using historical medical information from patients enrolled in the Effisayil™ 1 trial.
Background: Nonadherence to immune-modifying therapy is a complex behaviour which, before the COVID-19 pandemic, was shown to be associated with mental health disorders in people with immune-mediated diseases. The COVID-19 pandemic has led to a rise in the global prevalence of anxiety and depression, and limited data exist on the association between mental health and nonadherence to immune-modifying therapy during the pandemic.
Objectives: To assess the extent of and reasons underlying nonadherence to systemic immune-modifying therapy during the COVID-19 pandemic in individuals with psoriasis, and the association between mental health and nonadherence.
Article Synopsis
- * Research involving gene expression profiling of skin biopsies from DI-Pso patients revealed significant activation of the T helper 17/IL-23 pathways, alongside increased IL-36 expression, which is a marker of pustular psoriasis.
- * The findings indicate a shift in immune response from T helper 2 to T helper 17 in DI-Pso cases, coupled with notable skin barrier dysfunction compared to healthy individuals and those with other skin conditions.
Introduction: Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by flares of widespread erythema with sterile pustules, and can be relapsing with recurrent flares, or persistent with intermittent flares. Spesolimab, a humanized anti-interleukin-36 (IL-36) receptor monoclonal antibody, targets the key IL-36 pathogenetic pathway in GPP. A previous study showed that spesolimab treatment led to rapid pustular and skin clearance in patients with GPP flares, which was sustained for up to 12 weeks.
View Article and Find Full Text PDFArticle Synopsis
- - Generalized pustular psoriasis (GPP) is a severe and rare skin disease characterized by painful pustules and significant health risks, and recent evidence suggests it should be classified separately from psoriasis vulgaris (PV).
- - The article reviews the distinction between GPP and PV based on clinical and histopathological differences, as well as distinct genetic and immune system mechanisms that drive each condition.
- - GPP involves dysregulation of the innate immune system and is linked to the IL-36 inflammatory pathway, while PV is associated with the adaptive immune system and IL-17, indicating that a targeted treatment approach for GPP could lead to improved patient outcomes.
Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
J Eur Acad Dermatol Venereol
November 2022
Article Synopsis
- The study investigates the switching patterns between biologics in patients with moderate-to-severe plaque psoriasis, highlighting how these patterns have evolved with the introduction of new biologic treatments.
- In a cohort of 2,153 patients, it was found that 34% switched their first biologic within three years, primarily due to loss of efficacy (72%), with adalimumab and ustekinumab being the most commonly used agents.
- The research indicates that switching behaviors differ over time; for example, patients switching after 2016 were more likely to transition to IL-17 inhibitors rather than sticking with TNF-alpha inhibitors, signaling a shift in treatment preferences.
Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children.
View Article and Find Full Text PDF